China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 33.55 billion. The enterprise value is 28.41 billion.
| Market Cap | 33.55B |
| Enterprise Value | 28.41B |
Important Dates
The last earnings date was Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 17.47% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +17.47% |
| Shares Change (QoQ) | +1.82% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 14.85% |
| Float | 263.62M |
Valuation Ratios
The trailing PE ratio is 56.77 and the forward PE ratio is 39.45.
| PE Ratio | 56.77 |
| Forward PE | 39.45 |
| PS Ratio | 10.18 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 83.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.71, with an EV/FCF ratio of -83.73.
| EV / Earnings | 50.67 |
| EV / Sales | 8.62 |
| EV / EBITDA | 28.71 |
| EV / EBIT | 42.14 |
| EV / FCF | -83.73 |
Financial Position
The company has a current ratio of 5.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.85 |
| Quick Ratio | 4.87 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | -1.48 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 2.91% and return on invested capital (ROIC) is 4.52%.
| Return on Equity (ROE) | 2.91% |
| Return on Assets (ROA) | 1.96% |
| Return on Invested Capital (ROIC) | 4.52% |
| Return on Capital Employed (ROCE) | 3.08% |
| Weighted Average Cost of Capital (WACC) | 8.06% |
| Revenue Per Employee | 1.90M |
| Profits Per Employee | 323,182 |
| Employee Count | 1,764 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, Cathay Biotech has paid 100.66 million in taxes.
| Income Tax | 100.66M |
| Effective Tax Rate | 15.97% |
Stock Price Statistics
The stock price has decreased by -8.46% in the last 52 weeks. The beta is 0.71, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -8.46% |
| 50-Day Moving Average | 51.01 |
| 200-Day Moving Average | 50.78 |
| Relative Strength Index (RSI) | 44.05 |
| Average Volume (20 Days) | 4,142,268 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.30 billion and earned 560.72 million in profits. Earnings per share was 0.82.
| Revenue | 3.30B |
| Gross Profit | 1.13B |
| Operating Income | 674.20M |
| Pretax Income | 630.16M |
| Net Income | 560.72M |
| EBITDA | 989.80M |
| EBIT | 674.20M |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
The company has 9.25 billion in cash and 503.00 million in debt, with a net cash position of 8.75 billion or 12.14 per share.
| Cash & Cash Equivalents | 9.25B |
| Total Debt | 503.00M |
| Net Cash | 8.75B |
| Net Cash Per Share | 12.14 |
| Equity (Book Value) | 21.31B |
| Book Value Per Share | 24.68 |
| Working Capital | 9.72B |
Cash Flow
In the last 12 months, operating cash flow was 404.12 million and capital expenditures -743.46 million, giving a free cash flow of -339.34 million.
| Operating Cash Flow | 404.12M |
| Capital Expenditures | -743.46M |
| Depreciation & Amortization | 315.59M |
| Net Borrowing | -1.37B |
| Free Cash Flow | -339.34M |
| FCF Per Share | -0.47 |
Margins
Gross margin is 34.22%, with operating and profit margins of 20.46% and 17.02%.
| Gross Margin | 34.22% |
| Operating Margin | 20.46% |
| Pretax Margin | 19.12% |
| Profit Margin | 17.02% |
| EBITDA Margin | 30.04% |
| EBIT Margin | 20.46% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 0.85%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 0.85% |
| Dividend Growth (YoY) | 110.52% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 55.84% |
| Buyback Yield | -17.47% |
| Shareholder Yield | -16.62% |
| Earnings Yield | 1.67% |
| FCF Yield | -1.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |